Here are the S-3 shelf registrations from Kairos Pharma, Ltd. (KAPA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow KAPA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KAPA filings page.
Kairos Pharma, Ltd. has filed a shelf registration statement allowing it to offer up to $75,000,000 of common stock, preferred stock, debt securities, warrants and units over time. Within this, the company established an at‑the‑market equity program to sell up to $4,524,949 of common stock through H.C. Wainwright & Co. on the NYSE American.
Kairos is a clinical‑stage cancer drug developer with no approved products and no product revenue. It reported net losses of $4.1 million for the nine months ended September 30, 2025 and $2.6 million for 2024, with an accumulated deficit of about $12.9 million. As of January 12, 2026, public float was approximately $13,574,846, and the company is subject to limits that cap primary offerings under this registration at one‑third of its public float in any 12‑month period.
The filing details prior financing structures, including a $30 million equity line with Helena and a January 2025 PIPE that issued pre‑funded and common warrants, and explains that future proceeds from this shelf may support research and clinical development, working capital and other general corporate purposes.